Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis

As stereotactic body radiation therapy (SBRT) has shown to be effective and safe in patients with hepatocellular carcinoma (HCC), the aim of our propensity score matched analysis was to evaluate the efficacy of SBRT in comparison to transarterial chemoembolization (TACE) in intermediate and advanced...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2018-08, Vol.18 (1), p.807-9, Article 807
Main Authors: Bettinger, Dominik, Gkika, Eleni, Schultheiss, Michael, Glaser, Nicolas, Lange, Sophie, Maruschke, Lars, Buettner, Nico, Kirste, Simon, Nestle, Ursula, Grosu, Anca-Ligia, Thimme, Robert, Brunner, Thomas B
Format: Article
Language:English
Subjects:
Biopsy
Cancer patients
Cancer therapies
Care and treatment
Computed tomography
Duodenum
Health aspects
Hepatocellular carcinoma
Liver cancer
Medical imaging
Metastases
Metastasis
Mortality
NMR
Nuclear magnetic resonance
Overall survival
Patients
Portal vein
Propensity score analysis
Propensity scores
Quality of life
Radiation therapy
Radiofrequency ablation
Radiotherapy
Safety and security measures
Stereotactic body radiation therapy
Stomach
Thrombosis
Transarterial chemoembolization
Transplants & implants
Tumors
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c625t-5099b7f7dab44698395f1beabe15dd2d8947ab6c36f5f5904b1a72e239070ddc3
cites cdi_FETCH-LOGICAL-c625t-5099b7f7dab44698395f1beabe15dd2d8947ab6c36f5f5904b1a72e239070ddc3
container_end_page 9
container_issue 1
container_start_page 807
container_title BMC cancer
container_volume 18
creator Bettinger, Dominik
Gkika, Eleni
Schultheiss, Michael
Glaser, Nicolas
Lange, Sophie
Maruschke, Lars
Buettner, Nico
Kirste, Simon
Nestle, Ursula
Grosu, Anca-Ligia
Thimme, Robert
Brunner, Thomas B
description As stereotactic body radiation therapy (SBRT) has shown to be effective and safe in patients with hepatocellular carcinoma (HCC), the aim of our propensity score matched analysis was to evaluate the efficacy of SBRT in comparison to transarterial chemoembolization (TACE) in intermediate and advanced HCC. Patients treated with TACE (n = 367) and patients allocated to SBRT (n = 35) were enrolled in this study. Propensity score matching was performed to adjust for differences in baseline and tumor characteristics of TACE and SBRT patients. Local tumor control (LC) 1 year after treatment, overall survival (OS) and 1-year mortality were assessed. Patients treated with SBRT have received more prior HCC treatments compared to TACE patients. The LC 1 year after treatment in the unmatched cohort was 74.4% for TACE patients compared to 84.8% in the SBRT group. Patients treated with TACE showed significantly improved OS (17.0 months vs. 9.0 months, p = 0.016). After propensity score matching, the LC in the TACE (n = 70) and SBRT (n = 35) group was comparable (82.9% vs. 84.8%, p = 0.805) and OS did not differ significantly in both groups. SBRT after prior HCC therapy in selected patients shows comparable LC at 1 year, OS and 1-year mortality compared to patients treated with TACE.
doi_str_mv 10.1186/s12885-018-4696-8
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b7eac5ebbd354b8eb982066caecede70</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A556986230</galeid><doaj_id>oai_doaj_org_article_b7eac5ebbd354b8eb982066caecede70</doaj_id><sourcerecordid>A556986230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c625t-5099b7f7dab44698395f1beabe15dd2d8947ab6c36f5f5904b1a72e239070ddc3</originalsourceid><addsrcrecordid>eNptUl2L1DAULaK46-oP8EUCguBD16Rt0tSHhbGs7sCCsDs-h3zczmRomzFJ1fn3Zpx1nYLkIeHmnJObc0-WvSb4khDOPgRScE5zTHhesYbl_El2Tqqa5EWF66cn57PsRQhbjEnNMX-enZUYN0XNyXk2tG7YSW-DG5HrUO-07FGcBueRdmP0rkd2RDsZLYwxoJ82btBN26LoQUYwx8L9p7sVSozVor3-iCTaebeDMdi4R0E7D0iOst8HG15mzzrZB3j1sF9k3z5fr9qb_Pbrl2W7uM01K2jMKW4aVXe1kapKH-NlQzuiQCog1JjC8KaqpWK6ZB3taIMrRWRdQFE2uMbG6PIiWx51jZNbsfN2kH4vnLTiT8H5tZA-Wt2DUDVITUEpU9JKcVANLzBjWoIGAzVOWldHrd2kBjA6-eBlPxOd34x2I9buh2CYU0ZYEnj7IODd9wlCFFs3-eRIEAVucElpevAfai1TV3bsXBLTgw1aLChNJrCiPDRz-R9UWgYGmwYGnU31GeH9jHAYKvyKazmFIJb3d3PsuxPsBmQfN8H1U7RuDHMgOQK1dyF46B7dIFgckimOyRQpmeKQTMET582pjY-Mv1EsfwN-Md0m</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2090355206</pqid></control><display><type>article</type><title>Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis</title><source>PubMed Central (Open Access)</source><source>Publicly Available Content Database</source><creator>Bettinger, Dominik ; Gkika, Eleni ; Schultheiss, Michael ; Glaser, Nicolas ; Lange, Sophie ; Maruschke, Lars ; Buettner, Nico ; Kirste, Simon ; Nestle, Ursula ; Grosu, Anca-Ligia ; Thimme, Robert ; Brunner, Thomas B</creator><creatorcontrib>Bettinger, Dominik ; Gkika, Eleni ; Schultheiss, Michael ; Glaser, Nicolas ; Lange, Sophie ; Maruschke, Lars ; Buettner, Nico ; Kirste, Simon ; Nestle, Ursula ; Grosu, Anca-Ligia ; Thimme, Robert ; Brunner, Thomas B</creatorcontrib><description>As stereotactic body radiation therapy (SBRT) has shown to be effective and safe in patients with hepatocellular carcinoma (HCC), the aim of our propensity score matched analysis was to evaluate the efficacy of SBRT in comparison to transarterial chemoembolization (TACE) in intermediate and advanced HCC. Patients treated with TACE (n = 367) and patients allocated to SBRT (n = 35) were enrolled in this study. Propensity score matching was performed to adjust for differences in baseline and tumor characteristics of TACE and SBRT patients. Local tumor control (LC) 1 year after treatment, overall survival (OS) and 1-year mortality were assessed. Patients treated with SBRT have received more prior HCC treatments compared to TACE patients. The LC 1 year after treatment in the unmatched cohort was 74.4% for TACE patients compared to 84.8% in the SBRT group. Patients treated with TACE showed significantly improved OS (17.0 months vs. 9.0 months, p = 0.016). After propensity score matching, the LC in the TACE (n = 70) and SBRT (n = 35) group was comparable (82.9% vs. 84.8%, p = 0.805) and OS did not differ significantly in both groups. SBRT after prior HCC therapy in selected patients shows comparable LC at 1 year, OS and 1-year mortality compared to patients treated with TACE.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-018-4696-8</identifier><identifier>PMID: 30092781</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Biopsy ; Cancer patients ; Cancer therapies ; Care and treatment ; Computed tomography ; Duodenum ; Health aspects ; Hepatocellular carcinoma ; Liver cancer ; Medical imaging ; Metastases ; Metastasis ; Mortality ; NMR ; Nuclear magnetic resonance ; Overall survival ; Patients ; Portal vein ; Propensity score analysis ; Propensity scores ; Quality of life ; Radiation therapy ; Radiofrequency ablation ; Radiotherapy ; Safety and security measures ; Stereotactic body radiation therapy ; Stomach ; Thrombosis ; Transarterial chemoembolization ; Transplants &amp; implants ; Tumors ; Veins &amp; arteries</subject><ispartof>BMC cancer, 2018-08, Vol.18 (1), p.807-9, Article 807</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><rights>Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c625t-5099b7f7dab44698395f1beabe15dd2d8947ab6c36f5f5904b1a72e239070ddc3</citedby><cites>FETCH-LOGICAL-c625t-5099b7f7dab44698395f1beabe15dd2d8947ab6c36f5f5904b1a72e239070ddc3</cites><orcidid>0000-0002-8782-8729</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6085616/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2090355206?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30092781$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bettinger, Dominik</creatorcontrib><creatorcontrib>Gkika, Eleni</creatorcontrib><creatorcontrib>Schultheiss, Michael</creatorcontrib><creatorcontrib>Glaser, Nicolas</creatorcontrib><creatorcontrib>Lange, Sophie</creatorcontrib><creatorcontrib>Maruschke, Lars</creatorcontrib><creatorcontrib>Buettner, Nico</creatorcontrib><creatorcontrib>Kirste, Simon</creatorcontrib><creatorcontrib>Nestle, Ursula</creatorcontrib><creatorcontrib>Grosu, Anca-Ligia</creatorcontrib><creatorcontrib>Thimme, Robert</creatorcontrib><creatorcontrib>Brunner, Thomas B</creatorcontrib><title>Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>As stereotactic body radiation therapy (SBRT) has shown to be effective and safe in patients with hepatocellular carcinoma (HCC), the aim of our propensity score matched analysis was to evaluate the efficacy of SBRT in comparison to transarterial chemoembolization (TACE) in intermediate and advanced HCC. Patients treated with TACE (n = 367) and patients allocated to SBRT (n = 35) were enrolled in this study. Propensity score matching was performed to adjust for differences in baseline and tumor characteristics of TACE and SBRT patients. Local tumor control (LC) 1 year after treatment, overall survival (OS) and 1-year mortality were assessed. Patients treated with SBRT have received more prior HCC treatments compared to TACE patients. The LC 1 year after treatment in the unmatched cohort was 74.4% for TACE patients compared to 84.8% in the SBRT group. Patients treated with TACE showed significantly improved OS (17.0 months vs. 9.0 months, p = 0.016). After propensity score matching, the LC in the TACE (n = 70) and SBRT (n = 35) group was comparable (82.9% vs. 84.8%, p = 0.805) and OS did not differ significantly in both groups. SBRT after prior HCC therapy in selected patients shows comparable LC at 1 year, OS and 1-year mortality compared to patients treated with TACE.</description><subject>Biopsy</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Computed tomography</subject><subject>Duodenum</subject><subject>Health aspects</subject><subject>Hepatocellular carcinoma</subject><subject>Liver cancer</subject><subject>Medical imaging</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Overall survival</subject><subject>Patients</subject><subject>Portal vein</subject><subject>Propensity score analysis</subject><subject>Propensity scores</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Radiofrequency ablation</subject><subject>Radiotherapy</subject><subject>Safety and security measures</subject><subject>Stereotactic body radiation therapy</subject><subject>Stomach</subject><subject>Thrombosis</subject><subject>Transarterial chemoembolization</subject><subject>Transplants &amp; implants</subject><subject>Tumors</subject><subject>Veins &amp; arteries</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptUl2L1DAULaK46-oP8EUCguBD16Rt0tSHhbGs7sCCsDs-h3zczmRomzFJ1fn3Zpx1nYLkIeHmnJObc0-WvSb4khDOPgRScE5zTHhesYbl_El2Tqqa5EWF66cn57PsRQhbjEnNMX-enZUYN0XNyXk2tG7YSW-DG5HrUO-07FGcBueRdmP0rkd2RDsZLYwxoJ82btBN26LoQUYwx8L9p7sVSozVor3-iCTaebeDMdi4R0E7D0iOst8HG15mzzrZB3j1sF9k3z5fr9qb_Pbrl2W7uM01K2jMKW4aVXe1kapKH-NlQzuiQCog1JjC8KaqpWK6ZB3taIMrRWRdQFE2uMbG6PIiWx51jZNbsfN2kH4vnLTiT8H5tZA-Wt2DUDVITUEpU9JKcVANLzBjWoIGAzVOWldHrd2kBjA6-eBlPxOd34x2I9buh2CYU0ZYEnj7IODd9wlCFFs3-eRIEAVucElpevAfai1TV3bsXBLTgw1aLChNJrCiPDRz-R9UWgYGmwYGnU31GeH9jHAYKvyKazmFIJb3d3PsuxPsBmQfN8H1U7RuDHMgOQK1dyF46B7dIFgckimOyRQpmeKQTMET582pjY-Mv1EsfwN-Md0m</recordid><startdate>20180809</startdate><enddate>20180809</enddate><creator>Bettinger, Dominik</creator><creator>Gkika, Eleni</creator><creator>Schultheiss, Michael</creator><creator>Glaser, Nicolas</creator><creator>Lange, Sophie</creator><creator>Maruschke, Lars</creator><creator>Buettner, Nico</creator><creator>Kirste, Simon</creator><creator>Nestle, Ursula</creator><creator>Grosu, Anca-Ligia</creator><creator>Thimme, Robert</creator><creator>Brunner, Thomas B</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8782-8729</orcidid></search><sort><creationdate>20180809</creationdate><title>Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis</title><author>Bettinger, Dominik ; Gkika, Eleni ; Schultheiss, Michael ; Glaser, Nicolas ; Lange, Sophie ; Maruschke, Lars ; Buettner, Nico ; Kirste, Simon ; Nestle, Ursula ; Grosu, Anca-Ligia ; Thimme, Robert ; Brunner, Thomas B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c625t-5099b7f7dab44698395f1beabe15dd2d8947ab6c36f5f5904b1a72e239070ddc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biopsy</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Computed tomography</topic><topic>Duodenum</topic><topic>Health aspects</topic><topic>Hepatocellular carcinoma</topic><topic>Liver cancer</topic><topic>Medical imaging</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Overall survival</topic><topic>Patients</topic><topic>Portal vein</topic><topic>Propensity score analysis</topic><topic>Propensity scores</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Radiofrequency ablation</topic><topic>Radiotherapy</topic><topic>Safety and security measures</topic><topic>Stereotactic body radiation therapy</topic><topic>Stomach</topic><topic>Thrombosis</topic><topic>Transarterial chemoembolization</topic><topic>Transplants &amp; implants</topic><topic>Tumors</topic><topic>Veins &amp; arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bettinger, Dominik</creatorcontrib><creatorcontrib>Gkika, Eleni</creatorcontrib><creatorcontrib>Schultheiss, Michael</creatorcontrib><creatorcontrib>Glaser, Nicolas</creatorcontrib><creatorcontrib>Lange, Sophie</creatorcontrib><creatorcontrib>Maruschke, Lars</creatorcontrib><creatorcontrib>Buettner, Nico</creatorcontrib><creatorcontrib>Kirste, Simon</creatorcontrib><creatorcontrib>Nestle, Ursula</creatorcontrib><creatorcontrib>Grosu, Anca-Ligia</creatorcontrib><creatorcontrib>Thimme, Robert</creatorcontrib><creatorcontrib>Brunner, Thomas B</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bettinger, Dominik</au><au>Gkika, Eleni</au><au>Schultheiss, Michael</au><au>Glaser, Nicolas</au><au>Lange, Sophie</au><au>Maruschke, Lars</au><au>Buettner, Nico</au><au>Kirste, Simon</au><au>Nestle, Ursula</au><au>Grosu, Anca-Ligia</au><au>Thimme, Robert</au><au>Brunner, Thomas B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2018-08-09</date><risdate>2018</risdate><volume>18</volume><issue>1</issue><spage>807</spage><epage>9</epage><pages>807-9</pages><artnum>807</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>As stereotactic body radiation therapy (SBRT) has shown to be effective and safe in patients with hepatocellular carcinoma (HCC), the aim of our propensity score matched analysis was to evaluate the efficacy of SBRT in comparison to transarterial chemoembolization (TACE) in intermediate and advanced HCC. Patients treated with TACE (n = 367) and patients allocated to SBRT (n = 35) were enrolled in this study. Propensity score matching was performed to adjust for differences in baseline and tumor characteristics of TACE and SBRT patients. Local tumor control (LC) 1 year after treatment, overall survival (OS) and 1-year mortality were assessed. Patients treated with SBRT have received more prior HCC treatments compared to TACE patients. The LC 1 year after treatment in the unmatched cohort was 74.4% for TACE patients compared to 84.8% in the SBRT group. Patients treated with TACE showed significantly improved OS (17.0 months vs. 9.0 months, p = 0.016). After propensity score matching, the LC in the TACE (n = 70) and SBRT (n = 35) group was comparable (82.9% vs. 84.8%, p = 0.805) and OS did not differ significantly in both groups. SBRT after prior HCC therapy in selected patients shows comparable LC at 1 year, OS and 1-year mortality compared to patients treated with TACE.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>30092781</pmid><doi>10.1186/s12885-018-4696-8</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8782-8729</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2407
ispartof BMC cancer, 2018-08, Vol.18 (1), p.807-9, Article 807
issn 1471-2407
1471-2407
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_b7eac5ebbd354b8eb982066caecede70
source PubMed Central (Open Access); Publicly Available Content Database
subjects Biopsy
Cancer patients
Cancer therapies
Care and treatment
Computed tomography
Duodenum
Health aspects
Hepatocellular carcinoma
Liver cancer
Medical imaging
Metastases
Metastasis
Mortality
NMR
Nuclear magnetic resonance
Overall survival
Patients
Portal vein
Propensity score analysis
Propensity scores
Quality of life
Radiation therapy
Radiofrequency ablation
Radiotherapy
Safety and security measures
Stereotactic body radiation therapy
Stomach
Thrombosis
Transarterial chemoembolization
Transplants & implants
Tumors
Veins & arteries
title Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A24%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20local%20tumor%20control%20in%20patients%20with%20HCC%20treated%20with%20SBRT%20or%20TACE:%20a%20propensity%20score%20analysis&rft.jtitle=BMC%20cancer&rft.au=Bettinger,%20Dominik&rft.date=2018-08-09&rft.volume=18&rft.issue=1&rft.spage=807&rft.epage=9&rft.pages=807-9&rft.artnum=807&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-018-4696-8&rft_dat=%3Cgale_doaj_%3EA556986230%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c625t-5099b7f7dab44698395f1beabe15dd2d8947ab6c36f5f5904b1a72e239070ddc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2090355206&rft_id=info:pmid/30092781&rft_galeid=A556986230&rfr_iscdi=true